Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 27:13:77-87.
doi: 10.2147/CEOR.S290377. eCollection 2021.

Analysis of the Financial Impact of Using Cangrelor on the Safety and Efficacy Outcomes in Patients Undergoing Percutaneous Coronary Intervention in Whom Oral Therapy with P2Y12 Inhibitors is Not Feasible or Desirable, in Spain

Irene Lizano-Díez  1 , Silvia Paz Ruiz  2
Affiliations

Analysis of the Financial Impact of Using Cangrelor on the Safety and Efficacy Outcomes in Patients Undergoing Percutaneous Coronary Intervention in Whom Oral Therapy with P2Y12 Inhibitors is Not Feasible or Desirable, in Spain

Irene Lizano-Díez et al. Clinicoecon Outcomes Res. .

Abstract

Purpose: Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor indicated for the reduction of thrombotic cardiovascular events in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) in whom oral P2Y12 inhibitors are not feasible or desirable. The objective was to assess the financial impact of introducing cangrelor into the hospital formulary in Spain.

Patients and methods: A budget impact model was developed to calculate the cost difference between two scenarios (without and with cangrelor) to treat CAD patients undergoing PCI in whom oral P2Y12 inhibitors are not feasible or desirable, over 3 years. Intravenous P2Y12 inhibitor (cangrelor), oral P2Y12 inhibitors (clopidogrel, prasugrel, and ticagrelor), and glycoprotein IIb-IIIa inhibitors (GPIs) for bail-out use were considered. Epidemiological, efficacy (thrombotic events including cardiac death), safety (bleeding events), and costs (€, 2019) data were based on Spanish registries, clinical trials, and meta-analyses. One-way sensitivity analysis established the effect of uncertainty on results.

Results: For years 1, 2, and 3, the target population to receive cangrelor was 607, 1,822, and 3,340 patients, and cangrelor uptake was 23.70%, 58.30%, and 51.30%, respectively. The 3-year budget impact was 1,021,717€ varying from 50,245€ in year 1 to 599,272€ in year 3. The results were sensitive to the number of patients treated with GPIs in Spanish hospitals.

Conclusion: Based on our results, the financial effort needed to introduce the use of cangrelor in patients undergoing PCI in whom antiplatelet therapy with oral P2Y12 inhibitors is not feasible or desirable barely exceeds one million € over three years, in Spain.

Keywords: P2Y12 inhibitors; budget impact; cangrelor; percutaneous coronary intervention.

PubMed Disclaimer

Conflict of interest statement

ILD is an employee at Ferrer. SPR reports personal fees from Ferrer, during the conduct of the study. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Three years distribution of the total, primary PCI and PCI population in whom antiplatelet therapy with oral P2Y12 inhibitors is not feasible or desirable, in Spain.
Figure 2
Figure 2
Pharmacological and clinical event costs before and after introducing cangrelor into the hospital formulary in Spain for managing PCI patients in whom oral P2Y12 inhibitors are not feasible or desirable (three-year time horizon).
Figure 3
Figure 3
Tornado diagram: influence of key inputs on the budget impact of cangrelor for managing PCI patients in whom oral P2Y12 inhibitors are not feasible or desirable, in Spain.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Dégano IR, Elosua R, Marrugat J. Epidemiology of acute coronary syndromes in spain: estimation of the number of cases and trends from 2005 to 2049. Rev Esp Cardiol. 2013;66(6):472–481. doi:10.1016/j.recesp.2013.01.019 - DOI - PubMed
    1. Weintraub WS, Mandel L, Weiss SA. Antiplatelet therapy in patients undergoing percutaneous. coronary intervention: economic considerations. Pharmacoeconomics. 2013;31(11):959–970. doi:10.1007/s40273-013-0088-8.Antiplatelet - DOI - PMC - PubMed
    1. Cid Alvarez AB, Rodriguez Leor O, Moreno R, Peez de Prado A. Registro Español de Hemodinámica y Cardiología Intervencionista. XXVIII Informe Oficial de la Sección de Hemodinámica y Cardiología Intervencionista de la Sociedad Española de Cardiología (1990-2018) [Spanish Cardiac Catheterization and Coronary Intervent. Rev Esp Cardiol. 2019;72(12):1043–1053. doi:10.1016/j.recesp.2019.07.023 - DOI - PubMed
    1. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119–177. doi:10.1093/eurheartj/ehx393 - DOI - PubMed
    1. Collet J-P, Thiele H, Barbato E, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020;2020:1–79. - PubMed